Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy compared with other therapies for the treatment of COPD: a network meta-analysis
AS Ismaila, K Haeussler, A Czira, JH Youn… - Advances in …, 2022 - Springer
Abstract Introduction Randomized controlled trials (RCTs) comparing triple therapies
(inhaled corticosteroid [ICS], long-acting β2-agonist [LABA], and long-acting muscarinic …
(inhaled corticosteroid [ICS], long-acting β2-agonist [LABA], and long-acting muscarinic …
Stepwise management of COPD: What is next after bronchodilation?
M Miravitlles, K Matsunaga… - Therapeutic advances in …, 2023 - journals.sagepub.com
Inhaled bronchodilator therapy with long-acting muscarinic antagonists (LAMAs) and long-
acting β2-agonists (LABAs) in combination is currently the mainstay of treatment for chronic …
acting β2-agonists (LABAs) in combination is currently the mainstay of treatment for chronic …
Pharmacological therapy for stable chronic obstructive pulmonary disease
R Duan, B Li, T Yang - Chronic Diseases and Translational Medicine, 2023 - mednexus.org
In recent years, emphasis has shifted from preventing and treating chronic obstructive
pulmonary disease (COPD) to early prevention, early treatment, and disease stabilization …
pulmonary disease (COPD) to early prevention, early treatment, and disease stabilization …
A 7-point evidence-based care discharge protocol for patients hospitalized for exacerbation of COPD: consensus strategy and expert recommendation
Acute exacerbations of COPD (ECOPD) are an important event in the life of a COPD patient
as it causes significant deterioration of physical, mental, and social health, hastens disease …
as it causes significant deterioration of physical, mental, and social health, hastens disease …
Different inhaled corticosteroid doses in triple therapy for chronic obstructive pulmonary disease: systematic review and Bayesian network meta-analysis
HW Lee, HM Park, EJ Jang, CH Lee - Scientific reports, 2022 - nature.com
A systematic review and Bayesian network meta-analysis is necessary to evaluate the
efficacy and safety of triple therapy with different doses of inhaled corticosteroids (ICS) in …
efficacy and safety of triple therapy with different doses of inhaled corticosteroids (ICS) in …
[PDF][PDF] Impulse oscillometry, small airways disease, and extra-fine formulations in asthma and chronic obstructive pulmonary disease: windows for new opportunities
A Chetta, N Facciolongo, C Franco… - … and Clinical Risk …, 2022 - Taylor & Francis
In recent years, the perspective of management of respiratory disease has been gradually
changing in light of the increasing evidence of small airways as the major site of airflow …
changing in light of the increasing evidence of small airways as the major site of airflow …
Comparative effectiveness and safety of triple therapy and non-triple therapy interventions for COPD: an overview of systematic reviews
S Zhang, J Wang, X Li, H Zhang - Therapeutic Advances in …, 2024 - journals.sagepub.com
Background: Some systematic reviews (SRs) on triple therapy (consisting of long-acting β2-
agonist, long-acting muscarinic antagonist, and inhaled corticosteroid, LABA/LAMA/ICS) for …
agonist, long-acting muscarinic antagonist, and inhaled corticosteroid, LABA/LAMA/ICS) for …
Bayesian or frequentist: there is no question when comparing single-inhaler triple therapies via network meta-analysis. Focus on fluticasone furoate/umeclidinium …
L Calzetta, P Rogliani - Expert Review of Respiratory Medicine, 2023 - Taylor & Francis
Objectives Single-inhaler triple therapies (SITTs) have never been directly compared in
randomized controlled trials (RCTs) in chronic obstructive pulmonary disease (COPD) …
randomized controlled trials (RCTs) in chronic obstructive pulmonary disease (COPD) …
Effects of triple therapy on disease burden in patients of GOLD groups C and D: results from the observational COPD cohort COSYCONET
Background Randomized controlled trials described beneficial effects of inhaled triple
therapy (LABA/LAMA/ICS) in patients with chronic obstructive pulmonary disease (COPD) …
therapy (LABA/LAMA/ICS) in patients with chronic obstructive pulmonary disease (COPD) …
Mortality risk reduction with budesonide/glycopyrrolate/formoterol fumarate versus fluticasone furoate/umeclidinium/vilanterol in COPD: a matching-adjusted indirect …
D Stolz, E Hermansson, M Ouwens… - Current Medical …, 2023 - Taylor & Francis
Objective Chronic obstructive pulmonary disease (COPD) is a leading cause of death
worldwide. While two approved fixed-dose inhaled corticosteroid/long-acting muscarinic …
worldwide. While two approved fixed-dose inhaled corticosteroid/long-acting muscarinic …